Tampilkan postingan dengan label Statins and Alzheimers. Tampilkan semua postingan
Tampilkan postingan dengan label Statins and Alzheimers. Tampilkan semua postingan

Kamis, 03 Desember 2015

Statins associated with a 21% increased risk of Alzheimer's

This study was published in the Archives of Neurology 2005 Jul;62(7):1047-51

Study title and authors:
Statin use and the risk of incident dementia: the Cardiovascular Health Study.
Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH.
Department of Medicine, University of Washington, Seattle 98101, USA. rea123@u.washington.edu

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/16009757

The study investigated the association of statin use and the risk of dementia. Over an average period of 5.3 years, the study analysed 2,798 adults, aged 65 years and older, who were free of dementia at the start of the study.

The study found:
(a) Those who used statins had an 8% increased risk of dementia compared to those who had never used cholesterol lowering drugs.
(b) Those who used statins had an 21% increased risk of Alzheimer's compared to those who had never used cholesterol lowering drugs.



Links to other studies:
Statins may adversely affect cognition in patients with dementia
Statins have a significant negative impact on quality-of-life
Statin use associated with a 60% increased risk of dementia

Rabu, 30 September 2015

Statin use associated with a 60% increased risk of dementia

This study was published in Frontiers in Aging Neuroscience 2014 Nov 7;6:309

Study title and authors:
Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian Population.
Mandas A, Mereu RM, Catte O, Saba A, Serchisu L, Costaggiu D, Peiretti E, Caminiti G, Vinci M, Casu M, Piludu S, Fossarello M, Manconi PE, Dessí S.

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/25426067

One of the aims of the study was to establish whether a relationship exist between various types of dementia and statins and aspirin use. The study included 1,168 subjects 65 years or older.

The study found:
(a) Statin users had a 60% increased risk of any type of dementia compared to those not using statins.
(b) Statin users had a 90% increased risk of mild cognitive impairment compared to those not using statins.
(c) Statin users had a 70% increased risk of Alzheimer’s disease compared to those not using statins.
(d) Statin users had a 50% increased risk of mixed dementia compared to those not using statins.
(e) Statin users had a 40% increased risk of vascular dementia compared to those not using statins.
(f) Aspirin users had a 60% increased risk of any type of dementia compared to those not using Aspirin.
(g) Aspirin users had a 60% increased risk of mild cognitive impairment compared to those not using Aspirin.
(h) Aspirin users had a 10% increased risk of Alzheimer’s disease compared to those not using Aspirin.
(i) Aspirin users had a 150% increased risk of mixed dementia compared to those not using Aspirin.
(j) Aspirin users had a 70% increased risk of vascular dementia compared to those not using Aspirin.
(k) Statin and aspirin users had a 110% increased risk of any type of dementia compared to those not using statins and aspirin.
(l) Statin and aspirin users had a 170% increased risk of mild cognitive impairment compared to those not using statins and aspirin.
(m) Statin and aspirin users had a 60% increased risk of Alzheimer’s disease compared to those not using statins and aspirin.
(n) Statin and aspirin users had a 170% increased risk of mixed dementia compared to those not using statins and aspirin.
(o) Statin and aspirin users had a 110% increased risk of vascular dementia compared to those not using statins and aspirin.

The data from the study reveals that compared to statin non-users, statin users have a significantly higher risk of all types of dementia and with Alzheimer’s disease.

Mandas concluded: "Since cholesterol plays a fundamental role in the myelination of neurons, it has been proposed that excessive inhibition of cholesterol synthesis (by statins) could lead to adverse cognitive effects."

Selasa, 21 Oktober 2014

Statins have a significant negative impact on quality-of-life

This study was published in Pharmacotherapy 2009 Jul;29(7):800-11
 
Study title and authors:
Statin-associated adverse cognitive effects: survey results from 171 patients.
Evans MA, Golomb BA.
Department of Medicine, University of California-San Diego, La Jolla, California 92093-0995, USA.
 
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/19558254

The objective of the study was to characterize the adverse cognitive effects of statins. In the study, a survey was completed by 171 patients (age range 34-86 yrs) who had self-reported memory or other cognitive problems associated with statin therapy.

The study found:
(a) Of 143 patients who reported stopping statin therapy, 128 (90%) reported improvement in cognitive problems, sometimes within days of statin discontinuation.
(b) In some patients, a diagnosis of dementia or Alzheimer's disease reportedly was reversed.
(c) 19 patients whose symptoms improved or resolved after they discontinued statin therapy and who underwent rechallenge with a statin exhibited cognitive problems again (multiple times in some).
(d) Higher potency statins led to higher rates of cognitive-specific adverse drug reaction.
(e) Quality of life was significantly adversely affected.

Evans concludes: "Findings from the survey suggest that cognitive problems associated with statin therapy have variable onset and recovery courses, a clear relation to statin potency, and significant negative impact on quality-of-life".